Journals / Turkish Journal of Pharmaceutical Sciences / 2020 / Cilt: 17 - Sayı: 2

Statistical Design and Optimization of Sustained Release Formulations of Pravastatin

Pravastatinin Uzatılmış Salım Formülasyonlarının İstatistiksel Tasarım Kullanılarak Geliştirilmesi ve Optimizasyonu

Pages
221–227
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results showed that all the factorial batches werewithin the standard limits.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The objective of the current study was to formulate a sustained release (SR) formulation for pravastatin.
📊
Key Findings & Data:Pravastatin is a lipid lowering,biopharmaceutical classification class-III agent.Materials and Methods: SR tablets of pravastatin were prepared using variable amounts of hydroxy methyl propyl cellulose (HPMC) K4M and sodiumcarboxy methyl cellulose in various proportions by direct compression in a 32 factorial design.
💡
Conclusion & Impact:The results showed that all the factorial batches werewithin the standard limits.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The objective of the current study was to formulate a sustained release (SR) formulation for pravastatin. Pravastatin is a lipid lowering,biopharmaceutical classification class-III agent.Materials and Methods: SR tablets of pravastatin were prepared using variable amounts of hydroxy methyl propyl cellulose (HPMC) K4M and sodiumcarboxy methyl cellulose in various proportions by direct compression in a 32 factorial design. The amounts of the polymers HPMC K4M and sodiumcarboxy methyl cellulose required to obtain prolonged release of drug were chosen as independent variables, X1 and X2, respectively, whereas timestaken for 10%, 50%, 75%, and 90% drug release were chosen as dependent variables.Results: Nine formulations were developed and were checked using pharmacopoeial tests. The results showed that all the factorial batches werewithin the standard limits. The dissolution parameters of all formulations were subjected to kinetic fitting and various statistical parameters weredetermined. Polynomial equations were developed and verified for dependent variables. Formulation F5, containing 25 mg of HPMC K4M and 25mg of sodium carboxy methyl cellulose, was the formulation most similar (similarity factor f2=89.559, difference factor f1=1.546) to the marketedproduct (Pravachol).Conclusion: The best formulation (F5) follows Higuchi’s kinetics and non-Fickian diffusion zero order kinetics (n=1.083).

Özet

Amaç: Bu çalışmanın amacı, biyofarmasötik sınıflandırma sistemi III grubunda yer alan lipit düşürücü etkili pravastatinin sürekli salım yapan formülasyonunun geliştirilmesidir. Gereç ve Yöntemler: Pravastatin’in sürekli salım tabletleri, direkt kompresyonla 32faktöryel tasarıma göre çeşitli oranlarda hidroksi metil propil selüloz (HPMC) K4M ve sodyum karboksi metil selüloz kullanılarak hazırlanmıştır. Pravastatin’in uzun süreli salınımını elde etmek için bağımsız değişkenler olarak HPMC K4M (X1 ) ve sodyum karboksi metil selüloz (X2 ) miktarları; %10, %50, %75 ve %90 ilaç salımı için geçen süreler ise bağımlı değişkenler olarak seçilmiştir. Bulgular: Dokuz formülasyon geliştirilmiş ve bu formülasyonlara farmakopede belirtilen kontrol testleri uygulanmıştır. Sonuçlar geliştirilen tüm formülasyonların standart limit değerler arasında olduğunu göstermiştir. Tüm formülasyonların disolüsyon parametreleri kinetik modellere uygulanarak çeşitli istatistiksel parametreler belirlenmiştir. Polinomiyal denklemler bağımlı değişkenler için geliştirilmiş ve doğrulanmıştır. 25 mg HPMC K4M ve 25 mg sodyum karboksimetil selüloz içeren formülasyondan (F5 ) pravastatin salımı, ticari preparatı (Pravachol) ile benzer bulunmuştur (benzerlik faktörü f2 =89,559; fark faktörü f1 =1,546). Sonuç: En iyi formülasyonunun (F5 ), Higuchi kinetiği, Fick kanununa uymayan difüzyonun sıfırıncı derece kinetiğine (n=0,864) uygun davranış gösterdiği bulunmuştur.

🔖

Cite This Article

GUNDA, R. K., MANCHINENI, P. R. (2022). Statistical Design and Optimization of Sustained Release Formulations of Pravastatin. Turkish Journal of Pharmaceutical Sciences, Cilt: 17 - Sayı: 2, 221–227. https://ajindex.com/articles/654544

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Gunda RK, Kumar JNS, Babu CA, Anjaneyulu MV. Formulation development and evaluation of lamotrigine sustained release tablets using 32 factorial design. Int J Pharm Sci Res. 2015;6:1746-1752
  2. Bankar GS, Rhodes CT. Eds. Sustained and controlled drug delivery system. Modern Pharmaceutics (3rd ed). New York; Marcel Dekker Inc; 1996:668-669
  3. Lachmann L, Lieberman HA, Kanig JL. Sustained release dosage forms. The Theory & Practice of Industrial Pharmacy (3rd ed). Bombay; Varghese Publishing House; 1991:430-441
  4. Gunda RK. Formulation development and evaluation of rosiglitazone maleate sustained release tablets using 32 factorial design. Int J Pharm Tech Res. 2015;8:713-724
  5. Prakash P, Porwal M, Saxena A. Role of natural polymers in sustained release drug delivery system: application and recent approaches. Int Res J Pharmacy. 2011;2:6-11
  6. Rhodes CT, Robinson JR. Sustained and controlled drug delivery system. Modern Pharmaceutics (4th ed). New York; Marcel Dekker Inc; 2003:503-505
  7. Garg Y, Pathak K. Design and in vitro performance evaluation of purified microparticles of pravastatin sodium for intestinal delivery. AAPS Pharm Sci Tech. 2011;12:673-682
  8. Nilesh K, Komal JC, Abhijeet SK. Formulation and evaluation of self emulsifying drug delivery system of pravastatin sodium. Int J Inn Pharm Sci Res. 2015;3:527-550
  9. Maurya SK, Bali V, Pathak K. Bilayered transmucosal drug delivery system of pravastatin sodium: statistical optimization, in vitro, ex vivo, in vivo and stability assessment. Drug Delivery. 2012;19:45-57
  10. Shidhaye SS, Thakkar PV, Dand NM, Kadam VJ. Buccal drug delivery of pravastatin sodium. AAPS PharmSci Tech. 2010;11:416-424
  11. Boyong LI, Nangia A, Dely A, Wong D. Stable pharmaceutical compositions containing pravastatin. WO Patent. 03/000239; 2003
  12. Ramanathan A, Sreeja Sreekumar G. Development of chronomodulated drug delivery system of pravastatin sodium for the treatment of hypercholesterolemia. Der Pharm Sin. 2014;5:36-41
  13. Kapse Vidya N, Chemate SZ, Dharashive VM. Formulation development and solubility enhancement of rosuvastatin calcium tablet prepared by complexation with β-cyclodextrin by kneading method. Int J Pharm Sci Res. 2016;7:4882-4892
  14. Puttegowda VD, Karki R, Goli D, Jha SK, Mudagal MP. Formulation and pharmacokinetic evaluation of microcapsules containing pravastatin sodium using rats. Scientifica (Cairo). 2016;7623193
  15. Kumar JNS, Gunda RK. Design, formulation and evaluation of pravastatin f